Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -60.26% is 34% below its 5-year average of -45.08%, near the high end of its 5-year range (-2039.47%–28.00%).
85.56% below its 12-month average of -32.47%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 1.97%.
GROSS MARGIN
-60.26%
GROSS MARGIN AVG TTM
-32.47%
GROSS MARGIN AVG 3Y
-54.35%
GROSS MARGIN AVG 5Y
-45.08%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-85.56%
CURRENT VS 3Y AVG
-10.88%
CURRENT VS 5Y AVG
-33.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-245.63%
vs the sector median at left
Lucid Diagnostics Inc.
Market Cap
$114.79M
Gross Margin
-60.26%
TTM Avg
-32.47%
3Y Avg
-54.35%
5Y Avg
-45.08%
Market Cap
$115.67M
Gross Margin
89.22%
TTM Avg
94.61%
3Y Avg
97.31%
5Y Avg
-2138.81%
Market Cap
$113.89M
Gross Margin
-7075.00%
TTM Avg
-9131.25%
3Y Avg
-4667.52%
5Y Avg
-3111.68%
Market Cap
$113.77M
Gross Margin
99.91%
TTM Avg
-67.10%
3Y Avg
-31.47%
5Y Avg
-20.98%
Market Cap
$112.57M
Gross Margin
67.34%
TTM Avg
64.03%
3Y Avg
72.89%
5Y Avg
33.80%
Market Cap
$112.27M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
33.33%
Market Cap
$118.52M
Gross Margin
90.14%
TTM Avg
48.16%
3Y Avg
49.08%
5Y Avg
32.72%
Market Cap
$118.90M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
50.00%
5Y Avg
33.33%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $114.79M | -60.26% | -32.47% | -54.35% | -45.08% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | 89.22% | 94.61% | 97.31% | -2138.81% |
| Genelux Corporation (GNLX)vs › | $113.89M | -7075.00% | -9131.25% | -4667.52% | -3111.68% |
| MaxCyte, Inc. (MXCT)vs › | $115.69M | 79.43% | 81.39% | 84.94% | 86.41% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | 99.91% | -67.10% | -31.47% | -20.98% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | 67.34% | 64.03% | 72.89% | 33.80% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.27M | 0.00% | 0.00% | 50.00% | 33.33% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.52M | 90.14% | 48.16% | 49.08% | 32.72% |
| Spruce Biosciences, Inc. (SPRB)vs › | $118.90M | 0.00% | 50.00% | 50.00% | 33.33% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
-60.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 1.97% |
| 2026-03-31 | -47.05% |
| 2025-12-31 | -23.67% |
| 2025-09-30 | -40.13% |
| 2025-06-30 | -53.48% |
| 2025-03-31 | -87.32% |
| 2024-12-31 | -79.20% |
| 2024-09-30 | -43.69% |
| 2024-06-30 | -65.37% |
| 2024-03-31 | -65.43% |
| 2023-12-31 | -40.10% |
| 2023-09-30 | -108.68% |
| 2023-06-30 | -874.21% |
| 2023-03-31 | -200.00% |
| 2022-12-31 | -1344.64% |
| 2022-09-30 | -2039.47% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | -95.24% |
| 2021-12-31 | -46.91% |
| 2021-09-30 | 28.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2018-12-31 | 0.00% |
